TH169613A - NR2B selective Antagonist type - Google Patents
NR2B selective Antagonist typeInfo
- Publication number
- TH169613A TH169613A TH1601004025A TH1601004025A TH169613A TH 169613 A TH169613 A TH 169613A TH 1601004025 A TH1601004025 A TH 1601004025A TH 1601004025 A TH1601004025 A TH 1601004025A TH 169613 A TH169613 A TH 169613A
- Authority
- TH
- Thailand
- Prior art keywords
- compounds
- formula
- chemical formula
- salts
- useful
- Prior art date
Links
- 102000034577 retinoid X receptors Human genes 0.000 title claims abstract 5
- 108010038912 retinoid X receptors Proteins 0.000 title claims abstract 5
- 230000003042 antagnostic Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- 239000000126 substance Substances 0.000 claims abstract 5
- 210000003169 Central Nervous System Anatomy 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000011780 sodium chloride Substances 0.000 claims abstract 4
- 239000000470 constituent Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- -1 their salts Chemical class 0.000 claims abstract 2
Abstract
แก้ไข 30/09/2559 การเปิดเผยนี้โดยทั่วไปเกี่ยวข้องกับสารประกอบของสูตร I, ซึ่งรวมถึงเกลือของพวกมัน, และรวมถึงองค์ประกอบและวิธีใช้สารประกอบเหล่านี้ สารประกอบเหล่านี้เป็นลิแกนต์ของ NR2B รีเซพเตอร์และอาจใช้ประโยชน์สำหรับการรักษาของความผิดปกติต่างๆ ของระบบประสาท ส่วนกลาง (สูตรเคมี) I ------------------------------------------------------------------- การเปิดเผยนี้โดยทั่วไปเกี่ยวกับสารประกอบของสูตร I, ซึ่งรวมถึงเกลือของพวกมัน, และ รวมถึงองค์ประกอบและวิธีใช้สารประกอบเหล่านี้ สารประกอบเหล่านี้เป็นลิแกนต์ของ NR2B รีเซพเตอร์ และ อาจใช้ประโยชน์สำหรับการรักษาของความผิดปกติต่างๆ ของระบบประสาท ส่วนกลาง (สูตรเคมี) I สิทธิบัตรยา Correction 30/09/2016 This disclosure generally deals with the compounds of Formula I, which include their salts, and their composition and method of use. These compounds are NR2B receptor ligants and may be useful for the treatment of various disorders. Of the central nervous system (chemical formula) I ------------------------------------------ ------------------------- This general disclosure of Formula I compounds, including their salts, and their constituents and How to use these compounds These compounds are NR2B receptor ligants and may be useful for the treatment of various disorders. Of the central nervous system (chemical formula) I, drug patents.
Claims (1)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH169613B TH169613B (en) | 2017-10-27 |
| TH169613A true TH169613A (en) | 2017-10-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000541A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| BR112017026535A2 (en) | compound of formula I, isolated enantiomer, pharmaceutical composition, method for inhibiting mct4 monocarboxylate transporter activity, method for selectively inhibiting mct4 monocarboxylate transporter activity, method for treating a mct4 monocarboxylate transporter mediated disorder and use of a compound | |
| EA201790627A1 (en) | STEMULATORS RHC | |
| MX2016008128A (en) | Palatability enhancers for pet food, method of preparation and uses thereof. | |
| EA201791058A1 (en) | MORFOLIN- and 1,4-OXAZAZEPAN-AMIDA AS AN AGONISTS OF SOMATOSTATIN RECEPTOR Subtype 4 (SSTR4) | |
| MX2016008898A (en) | Selective nr2b antagonists. | |
| UY31448A1 (en) | COMPOUNDS OF 1,2,4, -TRIAZIN-3,5-DIONA SUITABLE FOR THE TREATMENT OF DISORDERS THAT RESPOND TO THE MODULATION OF THE DOPAMINE D3 RECEIVER. | |
| BR112018006537A2 (en) | selective nr2b antagonists | |
| CO2017010018A2 (en) | Derivatives of -2’-vinyl-abscisic acid (s) | |
| TH169613A (en) | NR2B selective Antagonist type | |
| TH169613B (en) | NR2B selective Antagonist type | |
| TH182729A (en) | Phenoxymethyl derivatives | |
| TH1801007671A (en) | Pyrazobopyrimidin derivatives as inhibitors of kinase reactions. | |
| TH1701002063A (en) | Aldosteron Synthes inhibitors | |
| TH1801001372A (en) | Process of antifungal compounds | |
| TH171926A (en) | Pyrazolo - pyridinamine replaced (SUBSTITUTED PYRAZOLO-PYRIDINAMINES). | |
| TH1701001398A (en) | 1-alkyl-6-oxo-1,6-dihydropyridin-3-il compounds And using it as a SGRM controller | |
| TH168893A (en) | Adenosine A1 agonist as an essential drug for kidney disease | |
| TH1801001807A (en) | An isoindolinone inhibitor of MDM2-P53 interaction with anticancer activity. | |
| TH1701003495A (en) | Triazolopyrimidine and its use | |
| TH174458A (en) | Pharmaceutical solids containing biotherin derivatives And the use of such elements | |
| TH146336A (en) | Pyridazinone compounds and their use as DAAO inhibitors | |
| TH134142A (en) | 2-Amino-3- (Imidazol-2-Il)-Piridin-4-Transfer Derivatives And its use as an inhibitor of VEGF receptor kinase | |
| TH158502A (en) | Heterocyclic compounds | |
| TH146335A (en) | New derivatives of 1,2,3,4-tetrahydroquinoline useful for the treatment of diabetes. |